(Q38100710)

28 August 2017

title

Cytochrome P450-mediated changes in oxycodone pharmacokinetics/pharmacodynamics and their clinical implications (English)

1 reference

28 August 2017

1 reference

1 reference

Lars L Gustafsson

3

0 references

author name string

Karin C Söderberg Löfdal

series ordinal

1

1 reference

28 August 2017

Marine L Andersson

series ordinal

2

1 reference

28 August 2017

language of work or name

1 reference

1 May 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

73

1 reference

28 August 2017

issue

6

1 reference

28 August 2017

page(s)

533-543

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

28 August 2017

1 reference

General practitioners' and hospital physicians' preference for morphine or oxycodone as first-time choice for a strong opioid: a National Register-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

Prescription of opioid analgesics and related harms in Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

The promotion and marketing of oxycontin: commercial triumph, public health tragedy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

Pharmacogenetics of opioids for the treatment of acute maternal pain during pregnancy and lactation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

Influence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

Personalized therapy in pain management: where do we stand?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

Complicated pain management in a CYP450 2D6 poor metabolizer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

Pharmacogenomics as molecular autopsy for postmortem forensic toxicology: genotyping cytochrome P450 2D6 for oxycodone cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

Uniform assessment and ranking of opioid μ receptor binding constants for selected opioid drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

How different is oxycodone from morphine?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

Antinociception by spinal and systemic oxycodone: why does the route make a difference? In vitro and in vivo studies in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

Pharmacological characterization of noroxymorphone as a new opioid for spinal analgesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

Mu receptor binding of some commonly used opioids and their metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

Is oxycodone efficacy reflected in serum concentrations? A multicenter, cross-sectional study in 456 adult cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

Characterization and validation of a pharmacokinetic model for controlled-release oxycodone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

The pharmacokinetics of oxycodone after intravenous injection in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

Plasma concentrations of oral oxycodone are greatly increased in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

A review of oxycodone's clinical pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

Genetic contribution to variable human CYP3A-mediated metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

CNVs of human genes and their implication in pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

Effect of telithromycin on the pharmacokinetics and pharmacodynamics of oral oxycodone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

Repeated administration of oxycodone modifies the gene expression of several drug metabolising enzymes in the hepatic tissue of male Sprague-Dawley rats, including glutathione S-transferase A-5 (rGSTA5) and CYP3A2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

Drugs as CYP3A probes, inducers, and inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

Intestinal first-pass metabolism of CYP3A4 substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

Functional interaction of intestinal CYP3A4 and P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

St John's wort greatly reduces the concentrations of oral oxycodone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

SFINX—a drug-drug interaction database designed for clinical decision support systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

Voriconazole drastically increases exposure to oral oxycodone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

Grapefruit juice enhances the exposure to oral oxycodone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

Absorption of different oral dosage forms of oxycodone in the elderly: a cross-over clinical trial in patients undergoing cystoscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0036-0

Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles

21 January 2018

1 reference

12 December 2020

The danger of imperfect regulation: OxyContin use in the United States and Canada

1 reference

12 December 2020

Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin

1 reference

12 December 2020

Lack of Association ofOPRM1andABCB1Single-Nucleotide Polymorphisms to Oxycodone Response in Postoperative Pain

1 reference

12 December 2020

CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure

1 reference

12 December 2020

The effects of the genetic absence and inhibition of CYP2D6 on the metabolism of codeine and its derivatives, hydrocodone and oxycodone

1 reference

12 December 2020

Oxycodone clearance is markedly reduced with advancing age: a population pharmacokinetic study

1 reference

12 December 2020

The pharmacokinetics of oxycodone

1 reference

12 December 2020

CYP3A5*3 affects plasma disposition of noroxycodone and dose escalation in cancer patients receiving oxycodone

1 reference

12 December 2020

The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone

1 reference

12 December 2020

Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype

1 reference

12 December 2020

Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population

1 reference

12 December 2020

Effects of voriconazole co-administration on oxycodone-induced adverse events: a case in the retrospective survey

1 reference

12 December 2020

Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis

1 reference

12 December 2020

Elimination of intravenous oxycodone in the elderly: a pharmacokinetic study in postoperative orthopaedic patients of different age groups

1 reference

12 December 2020

Inhibition of Cytochrome P450 3A by Clarithromycin Uniformly Affects the Pharmacokinetics and Pharmacodynamics of Oxycodone in Young and Elderly Volunteers

1 reference

12 December 2020

Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction.

1 reference

12 December 2020

Oxymorphone and oxymorphone extended release: a pharmacotherapeutic review.

1 reference

12 December 2020

Effect of inhibition of cytochrome P450 enzymes 2D6 and 3A4 on the pharmacokinetics of intravenous oxycodone: a randomized, three-phase, crossover, placebo-controlled study

1 reference

12 December 2020

Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone

1 reference

12 December 2020

10.1007/S40265-013-0036-0

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1041719102

0 references

1 reference